CB Insights names ER as key China pharma investor

Eight Roads is included in CB Insights' ranking of China Innovative Drug Early Stage Investors.

Eight Roads has a strong credential in healthcare investment. It was the founding investor of Innovent Biologics, Hua Medicine, Adagene and Citrine Medicine. It also invested in Semma Therapeutics, Shouti and Insilico Medicine.

Dr. Feng Zhao joins as Venture Partner

読了時間

Rare disease platform Citrine Medicine raises $80m

読了時間

OcuMension Therapeutics lists on HKEx

読了時間

Otrium raises €24M to extend fashion’s life cycle

読了時間

The information on these pages is intended solely for the benefit of entrepreneurs and businesses seeking venture capital investment. Eight Roads does not offer and is not offering to provide investment advisory services nor is it offering to engage in any transactions in securities.

Related Articles